Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

<i>Background and Objectives:</i> Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectiveness and safet...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2024-07-01
Serie:	Medicina
Soggetti:	alirocumab evolocumab inclisiran hypercholesterolemia proprotein convertase subtilisin/kexin type 9 inhibitors
Accesso online:	https://www.mdpi.com/1648-9144/60/7/1124
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!